Moxetumomab pasudotox
Lumoxiti (moxetumomab pasudotox) is an antibody pharmaceutical. Moxetumomab pasudotox was first approved as Lumoxiti on 2018-09-13. It is used to treat hairy cell leukemia in the USA. The pharmaceutical is active against B-cell receptor CD22.
| Trade Name | Lumoxiti |
|---|---|
| Common Name | Moxetumomab pasudotox |
| Indication | hairy cell leukemia |
| Drug Class | Monoclonal antibodies |
